Niagen Bioscience (NAGE) Insider Patrick Buys 31,746 Shares
Kristin Patrick purchased 31,746 shares of Niagen Bioscience on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kristin Patrick bought 31,746 shares of Niagen Bioscience, Inc. ($NAGE) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAGE is down 3.5% after 1 week, down 7.0% after 1 month and down 27.8% to date (from the $3.45 close on Jun 24, 2026).
NAGE
Niagen Bioscience, Inc.
Key Points
- On June 24, 2026, Kristin Patrick bought 31,746 shares of Niagen Bioscience, valued at approximately $108,000 based on a share price of $3.42.
- This purchase adds to a series of insider transactions on the same day, with other insiders also acquiring 31,746 shares each.
- Niagen Bioscience has a market cap of about $240.5 million and operates in the consumer defensive sector, focusing on healthy aging products.
Get $NAGE trade alerts by text
We text you when insiders, Congress or big funds trade $NAGE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Niagen Bioscience, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Niagen Bioscience, Inc.
Kristin Patrick bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) on June 24, 2026. The shares were purchased at a price of $3.42 each, making the total value of the transaction approximately $108,000, according to the latest SEC filing.
Other Insiders Join In
On the same day, several other insiders also made similar purchases. Yu Wing Tak Wendy, Hamed Shahbazi, Steven Rubin, Ann Cohen, Ng Wang Yu Gary, and Jaksch Frank Jr. each bought 31,746 shares of Niagen Bioscience. This indicates a strong level of insider confidence in the company, with each insider making a significant investment.
How Niagen Bioscience, Inc. Stock Has Traded
Niagen Bioscience shares were trading at $3.42 as of June 24, 2026. The stock is currently above its 52-week low of $2.87 but well below its high of $10.52. This recent insider buying comes as the company operates in a sector focused on health and wellness, which can be appealing to investors.
What Niagen Bioscience, Inc. Does
Niagen Bioscience, Inc. specializes in developing products for healthy aging. The company provides dietary supplements and various proprietary ingredients, including nicotinamide adenine dinucleotide (NAD+), essential for cellular metabolism. This focus on health products may have influenced the recent insider buying activity.
What’s Next for Niagen?
Investors will be watching for Niagen's next earnings report scheduled for November 3, 2026. The recent insider trades reflect a strong belief in the company's potential, but further filings and market performance will be crucial to observe.
Related Filing Alerts
Source: Kristin Patrick's Form 4 filing on $NAGE (Jun 24, 2026). Find the original filing: NAGE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts